#United States #New York #Class Action #Gross Law Firm #Inc. #DexCom

DexCom, Inc. Shareholders: Important Call to Action

The Gross Law Firm has issued a significant notice for shareholders of DexCom, Inc. (NASDAQ: DXCM), urging those who purchased shares during a specific timeframe to take action. If you are among the affected investors, it is essential to understand the implications of this class action lawsuit and your potential rights as a shareholder.

Background

From January 8, 2024, to September 17, 2025, DexCom shareholders may have experienced financial losses attributed to alleged misleading claims made by the company regarding its glucose monitoring devices, specifically the G6 and G7 models. These products are crucial for individuals who rely on accurate glucose readings for managing their health, and any misinformation can have severe consequences.

Allegations against DexCom

The complaint outlines several serious allegations:
1. Material Misrepresentation: During the class period, DexCom allegedly issued false and misleading statements about the reliability and accuracy of the G6 and G7 glucose monitoring devices.
2. Unauthorized Design Changes: It is claimed that DexCom made significant design alterations to these devices without proper authorization from the U.S. Food and Drug Administration (FDA).
3. Health Risks: These design changes purportedly compromised the accuracy of the glucose readings, posing material health risks to users.
4. False Enhancements: The company’s claims regarding improvements to the G7’s efficacy were allegedly overstated, masking the true scope of the problems.
5. Regulatory Scrutiny: The misleading information had the potential to expose DexCom to heightened regulatory scrutiny, which could result in legal and financial repercussions for the company.

How to Participate in the Class Action

Shareholders who bought shares of DexCom during the specified period are encouraged to reach out to The Gross Law Firm to discuss possible lead plaintiff appointment. It's important to note that becoming a lead plaintiff is not obligatory for participating in any recovery from the lawsuit.

To register your involvement, visit the Gross Law Firm’s registration page and ensure your information is submitted before the December 26, 2025 deadline. Once you register, you will be enrolled in an ongoing portfolio monitoring system that will provide updates on the case’s progress, helping you stay informed about any developments.

Why Choose The Gross Law Firm?

The Gross Law Firm is renowned for advocating on behalf of investors impacted by fraudulent practices and misconduct. Their commitment lies in safeguarding the rights of investors who have sustained losses due to misleading corporate conduct. They’ve built a strong reputation in the realm of class action lawsuits, focusing on ensuring companies maintain accountability and transparency.

If you’re a DexCom shareholder affected by these circumstances, do not hesitate to secure your place in this critical legal action. Your participation may help ensure that DexCom is held accountable for any possible wrongdoing and may lead to recovery of losses incurred during the class period.

For more information, or to discuss your potential case, contact The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Make sure to act quickly—your rights as a shareholder depend on your timely response to this situation.